Reg Jones, CFO of Stratagene, will retire at the end of June, the company announced last week. Jones has spent the past 24 years with Stratagene and Hycor Biomedical, which Stratagene acquired in June 2004.
Steve Martin, currently Stratagene's director of finance, will succeed Jones as CFO on July 1. He joined Stratagene last year and was responsible for integrating the accounting and reporting for all entities connected to the merger. Martin spent 10 years with accounting firm Deloitte & Touche, and previous to joining Stratagene held the post of controller at Gen-Probe.
The Ontario Genomics Institute has named five new directors to its board: John Molloy, president and chief executive officer of Parteq Innovations; Mark Poznansky, president and scientific director of the Robarts Research Institute; Cheryl Reicin, practice leader of the technology and life sciences group at Torys; Niclas Stiernholm, chief executive officer of Trillium Therapeutics; and Brian Underdown, managing director of technology investing at MDS Capital.
Molloy holds an MBA from Queen's University, Poznansky received a PhD in physiology from McGill University, Reicin has a JD from Harvard Law School and a BA from Columbia University, Stiernholm holds a PhD in immunology from the University of Toronto, and Underdown has a PhD in immunology from Washington University in St. Louis.